Biogen - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Biogen
BIIB
|
NASDAQ
|
United States
865
-305
Rank
$32.85B
Market Cap
$9.67B
-$ 0.16B
-1.63%
Revenue
$1.90B
+$ 0.61B
+47.29%
Earnings
7.6K
+0K
+0.46%
Employees
About
Biogen, Inc. (BIIB)
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands
31.10.2025 -
Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative
31.10.2025 -
Biogen (BIIB) Valuation: Exploring the Discount as Investor Sentiment Shifts
31.10.2025 -
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
29.10.2025 -
Newleos Therapeutics CEO David Donabedian Recognized by Goldman Sachs as One of the Most Exceptional Entrepreneurs at the 2025 Builders and Innovators Summit
15.10.2025